Background-Interpretation of measurements of limited maximal airway narrowing, or plateau response, requires knowledge of its variability within subjects and between methods. Methods-The repeatability of the plateau response to inhaled methacholine with a dosimeter (D) method (maximal dose 210 umol) and a tidal breathing (T) method (730 ,umol), and the agreement of the two methods, were measured in 16 subjects with mild or no asthma. Two tests by each method (D1,D2,T1,T2) were performed in random order over four consecutive days, with a third dosimeter (D3) test one week later. The dose producing a decrease in forced expiratory volume in one second (FEV,) of 10% (PD10) and the plateau were calculated from each dose-response curve.
Methods-The repeatability of the plateau response to inhaled methacholine with a dosimeter (D) method (maximal dose 210 umol) and a tidal breathing (T) method (730 ,umol) , and the agreement of the two methods, were measured in 16 subjects with mild or no asthma. Two tests by each method (D1,D2,T1,T2) were performed in random order over four consecutive days, with a third dosimeter (D3) test one week later. The dose producing a decrease in forced expiratory volume in one second (FEV,) of 10% (PD10) and the plateau were calculated from each dose-response curve.
Results-A plateau was reached in all five tests in 12 subjects and in all tests except D3 in 14 subjects. PD,o was inversely related to the plateau (r = -0 95 for D, r = -0 77 for T). The 95% ranges for differences between two determinations of the plateau in a subject were 1190/o (change in FEV1), ± 19-2%, and ± 20-3%, estimated from D1-2 and 1-3, and T1-2 tests, respectively. From the same tests the 95% ranges for the difference of a single determination from an individual's true mean value were _ 8*3%, ± 13-6%, and ± 14-3%. The limits of agreement between methods indicated that 95% of the measurements of the plateau by tidal breathing ranged from 15-2% below to 13-3% above those obtained by dosimeter. There was no significant bias between methods. Tachyphylaxis over 24 hours occurred with PD,o but not with the plateau response. Conclusions-The plateau response is a subject characteristic which is independent of the method of inhalation challenge testing. Repeatability of the plateau is low in this group of subjects with low airway responsiveness. (Thorax 1993; 48:512-517) Bronchial responsiveness is often assessed by measuring the changes in lung function induced by inhaling increasing doses of bronchoconstricting agents such as methacholine. The two most commonly used methods of inhalation challenge testing are the tidal breathing method' 2 and the dosimeter method.34 The position5 and shape6 of the dose-response curves obtained differ in patients with asthma from those in normal subjects. In patients with asthma the curve is shifted to the left, reflecting increased airway sensitivity.5 This is commonly expressed as the provocative concentration (PC20)l or dose (PD20)3 causing a 20% fall in forced expiratory volume in one second (FEV,).
It has been noted that the dose-response curves are sigmoid in shape and reach a maximum response (plateau) in individuals with normal or mildly increased airway sensitivity.67 Individuals with moderate or severe asthma fail to reach a plateau despite a fall in FEV, of up to 60%.6 It has been proposed that the presence of a plateau response indicates a limit to the degree to which airways can narrow, while moderate to severe asthma is characterised by the absence of such a limitation to maximal airway narrowing.67
The possibility that the level of the plateau response is related to the method of inhalation challenge has not been fully investigated. If the plateau is a stable characteristic of an individual, it should be similar with different methods of testing. The aims of this study were to assess the repeatability of the plateau response in subjects with no asthma or with mild asthma by a dosimeter method and a tidal breathing method, and to assess the agreement between the two methods.
Methods

SUBJECTS
Sixteen adult volunteers from the hospital and laboratory staff took part in the study (table 1) . Subject no. 6 had had intermittent wheeze and chest tightness within the previous month and was taking salbutamol as required and regular beclomethasone but did not use salbutamol within six hours of testing on any of the test days. Two subjects had a previous history of asthma but were free of symptoms at the time of the study and were not taking medication. Seven subjects had a history of hay fever although none had any respiratory symptoms during the period of the study. Atopic state was not tested and no subject had an upper respiratory infection. All For the dosimeter method paired t tests were also used to examine differences between day 1 and day 7, and between days 2, 3, or 4 and day 7. The within subject repeatability of the level of the plateau measured by each method and the agreement between the two methods were analysed by the method described by Bland and Altman.'011 All analyses of PD1o were performed on logarithmically transformed data (base 10). The repeatability of each method was assessed from the mean (x) and standard deviation (SD) of individual differences between replicates, and the within subject standard deviation (ar). Where (x1-x2) was the difference between replicates by a given method, the formulae were: SD = l(Z7 (x1 -x,)2/n) ar = I(Zn(xI -x2)2/2n) = SD/12 These two values provide 95% ranges which have different implications. The 95% range based on ± 2 SD values represents the range for change from one test to the next. The 95% range based on ± 2 ur represents the interval within which 95% of the differences between a single determination and that individual's true mean measurement will lie. The 95% ranges were corrected for sample size by the t distribution.'2 Where SD (or ur) was on a log scale, the 95% ranges were calculated by antilog transformation.
Independence of repeatability from the size of the measurements was assessed by plotting the absolute value of individual differences between replicates against the individual means of the replicates, and comparing the correlation coefficient (r) with the null hypothesis of r = 0.
Agreement between methods was assessed by analysing the individual differences between the means of replicates for each method. The mean (x) of the differences between each method was the bias. A paired t test examined the hypothesis of zero bias. Since the SD of the differences is underestimated when replicates are averaged, the corrected SD (SDJ) was: 4(SD2 + 1/4SD2 + 1/4ST2), where SD and ST are the SD values of differences between replicates for the dosimeter and tidal breathing methods respectively. Limits of agreement were estimated as x ± 2SDC. Independence of agreement between methods from the size of the measurements was assessed by plotting the individual differences between the means of replicates for each method against the individual averages of the means of the two methods, and comparing r with the null hypothesis of r = 0.
Results
A plateau was reached in all five tests in 12 subjects, and in all but the third dosimeter test in an additional two subjects (table 3) . Replicates of the plateau response were available in all subjects for the first two dosimeter tests, and in 14 subjects for the tidal breathing tests. One subject (no. 8) stopped one test because of dyspnoea before a plateau was reached. In three subjects the FEV1 continued to change by more than 5% per dose step without reaching a plateau by the final dose of methacholine. Subject no. 6, with current asthma, had a fall in FEVy greater than 50% on one occasion. A PD1o could be measured at least once for all subjects. There was a close inverse relationship between log PD,0 and the plateau response, r = -095, p < 0-001 for the first dosimeter test and r = -0-77, p <0-01 for the first tidal breathing test (fig 1) .
REPEATABILITY
The baseline FEV1 did not change significantly from day to day (fig 2) . The order in which the tests were performed affected the PD10 and plateau response differently (fig 2) .
For each subject the plateau responses were not significantly different on any test day with either method. PD10 was, however, signifi- The high values for expected change from one test to the next (low repeatability) are likely to result from studying subjects with very mild airway responsiveness. Flat doseresponse curves will exaggerate differences between tests in the same subject, especially since measurements of PD,o and plateau were made on the flat portion of the dose-response curve. In subjects with asthma the doseresponse curve is steeper and much greater within subject repeatability for PD,0 has been reported. '4 In addition, the variability of PD20 is greater at higher doses of inhaled agonist. '5 There is no previous report of the repeatability of the plateau response with a dosimeter method. Sterk et al7 reported the plateau response to be highly reproducible by a tidal breathing method, with an intraclass correlation coefficient of 088. This statistic depends in part on between subject variance, and there is debate about the best method of assessing repeatability.'6 Reanalysis of their data by the method described by Bland and Altman''ll yields a coefficient of repeatability for the maximal plateau response of + 7-8%-that is, a difference between two estimates of the plateau response of more than 8% change in FEVy was likely to be significant. This is similar to the value of 12% we obtained for the dosimeter method but half the value for the tidal breathing method. Possible reasons for this discrepancy include differences in subject characteristics as mentioned above. Furthermore, in their calculations of the maximal response, Sterk et al7 included subjects who did not reach a plateau per se and substituted the absolute maximal change, whereas the present study excluded subjects from further analysis if replicates were not available.
In the present study the airway response, assessed by PD1,o showed tachyphylaxis at intervals of 24 hours. This effect had disappeared after one week and the plateau response was not subject to tachyphylaxis. The results of this study suggest, however, that, although tachyphylaxis can shift the in vivo dose-response curve to the right, it does not reduce maximal airway narrowing. The factors that normally limit airway narrowing and determine the level of the plateau response include those limiting stimulation of smooth muscle, local neurohumoral influences, and the structural relationships between the airway wall tissues including smooth muscle and the surrounding elastic parenchyma."7 Many of these factors are unlikely to change over a short period of time.
There was no bias between methods in assessing the level of the plateau response, indicating that the methods were, on average, measuring the same property of the airways and suggesting that the measured plateau response was independent of the method of inhalation challenge testing used. Agreement between the two methods was, however, not high. This was probably partly because of the relatively less repeatable tidal breathing results, as agreement between methods is bound to be poor if either method is not repeatable.
This study confirms the inverse relationship between PD,, and the plateau response reported previously by Sterk et al. 7 This association is likely to reflect the fact that both parameters are related to some common factor determining bronchial responsiveness.
The observation of tachyphylaxis of the PDo,, but not of the plateau response, shows that they can behave independently and this is supported by studies undertaken elsewhere. '8-20 The usefulness of measurements of the maximal (plateau) response to inhaled bronchoconstricting agents remains to be determined. The maximal response may be a more useful predictor of symptom severity2l and a means of monitoring the efficacy of treatment." To be used in this manner, more information is needed on the stability of the maximal response in larger numbers of normal subjects and patients with mild asthma.
